COQ2 encodes the enzyme coenzyme-Q2-polyprenyltransferase in the biosynthetic pathway of coenzyme Q
10. Coenzyme Q
10 is an integral part of the mitochondrial electron transport chain; it transfers electrons from complex I and II to complex III [
21]. Deficiencies in coenzyme Q
10 cause mitochondrial dysfunction, oxidative stress and reduced ATP synthesis [
62]. Polymorphisms in
COQ2 have been associated with MSA in several studies. In one study, functionally-impaired
COQ2 V393A variant was shown to be associated with sporadic MSA in a Japanese population [
46]. This association was supported by a meta-analysis in a subsequent study, in which V393A was shown to be associated with increased risk of MSA in Han Chinese, Japanese and possibly broader East Asian populations [
93]. In contrast, another study showed that V393A was not associated with MSA in 133 Japanese MSA patients [
77]. Likewise, V393A was not associated with MSA in Korean MSA patients [
35]. Apart from V393A, other
COQ2 variants (e.g. L25 V, M128 V, R173H, L402F, A32A and N386I) have been identified in various populations [
16,
46,
77,
85]. The pathological link between
COQ2 and MSA was strengthened when it was discovered that plasma coenzyme Q
10 levels were lower in MSA patients compared to healthy controls [
48]. Furthermore, coenzyme Q
10 levels were found to be lower in the cerebellum, along with increases in mitochondrial dysfunction and oxidative stress, in MSA cases compared to controls [
7]. Interestingly, these changes occurred in MSA cases in the absence of any
COQ2 variants associated with MSA [
7]. Overall, current evidence cannot fully exclude that specific
COQ2 variants are associated with MSA in only certain populations or ethnic groups, but that this pathway may be vulnerable to MSA. Further research is required to determine how
COQ2 may contribute to MSA pathogenesis and to reconcile the differences in different ethnic groups.